Biomea Fusion (BMEA) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

BMEA Stock Forecast


Biomea Fusion stock forecast is as follows: an average price target of $22.75 (represents a 157.35% upside from BMEA’s last price of $8.84) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

BMEA Price Target


The average price target for Biomea Fusion (BMEA) is $22.75 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $11.00. This represents a potential 157.35% upside from BMEA's last price of $8.84.

BMEA Analyst Ratings


Buy

According to 8 Wall Street analysts, Biomea Fusion's rating consensus is 'Buy'. The analyst rating breakdown for BMEA stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Biomea Fusion Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Joseph CatanzaroPiper Sandler$19.00$10.3483.75%114.93%
Oct 30, 2024Peter LawsonBarclays$11.00$12.06-8.79%24.43%
Oct 22, 2024Joseph PantginisH.C. Wainwright$40.00$11.24255.87%352.49%
Sep 27, 2024Joseph CatanzaroPiper Sandler$10.00$9.901.01%13.12%
Jun 07, 2024Joseph PantginisH.C. Wainwright$15.00$4.24253.78%69.68%
Jun 07, 2024George FarmerScotiabank$21.00$11.2786.34%137.56%
Jun 07, 2024Peter LawsonBarclays$5.00$11.27-55.63%-43.44%
Jun 14, 2022Joseph PantginisH.C. Wainwright$16.00$8.5088.22%81.00%
Row per page
Go to

The latest Biomea Fusion stock forecast, released on Oct 31, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $19.00, which represents a 83.75% increase from the stock price at the time of the forecast ($10.34), and a 114.93% increase from BMEA last price ($8.84).

Biomea Fusion Price Target by Period


1M3M12M
# Anlaysts347
Avg Price Target$23.33$20.00$17.29
Last Closing Price$8.84$8.84$8.84
Upside/Downside163.91%126.24%95.59%

In the current month, the average price target of Biomea Fusion stock is $23.33, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 163.91% increase as opposed to Biomea Fusion's last price of $8.84. This month's average price target is up 16.65% compared to last quarter, and up 34.93% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024Piper SandlerOverweightOverweightHold
Oct 30, 2024BarclaysEqual-WeightEqual-WeightHold
Oct 22, 2024H.C. WainwrightBuyBuyHold
Oct 09, 2024EF Hutton-BuyInitialise
Sep 27, 2024ScotiabankOutperformOutperformHold
Sep 27, 2024Piper SandlerOverweightOverweightHold
Sep 27, 2024ScotiabankSector OutperformSector OutperformHold
Sep 27, 2024H.C. WainwrightBuyBuyHold
Sep 27, 2024BarclaysEqual-WeightEqual-WeightHold
Sep 26, 2024Rodman & RenshawNeutralBuyUpgrade
Row per page
Go to

Biomea Fusion's last stock rating was published by Piper Sandler on Oct 31, 2024. The company gave BMEA a "Overweight" rating, the same as its previous rate.

Biomea Fusion Financial Forecast


Biomea Fusion Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue---------------
Avg Forecast---------------
High Forecast---------------
Low Forecast---------------
# Analysts---------------
Surprise %---------------

Biomea Fusion's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BMEA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Biomea Fusion EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts---------------
EBITDA---------------
Avg Forecast---------------
High Forecast---------------
Low Forecast---------------
Surprise %---------------

undefined analysts predict BMEA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biomea Fusion's previous annual EBITDA (undefined) of $NaN.

Biomea Fusion Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts---------------
Net Income---------------
Avg Forecast$-28.96M$-27.91M$-25.79M$-24.74M$-30.90M$-29.79M$-27.52M$-26.40M$-43.71M$-41.29M$-37.55M$-36.34M$-33.18M$-34.21M$-38.81M
High Forecast$-28.96M$-27.91M$-25.79M$-24.74M$-30.90M$-29.79M$-27.52M$-26.40M$-43.71M$-41.29M$-37.55M$-32.71M$-29.61M$-34.21M$-38.81M
Low Forecast$-28.96M$-27.91M$-25.79M$-24.74M$-30.90M$-29.79M$-27.52M$-26.40M$-43.71M$-41.29M$-37.55M$-43.61M$-39.04M$-34.21M$-38.81M
Surprise %---------------

Biomea Fusion's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BMEA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Biomea Fusion SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts---------------
SG&A---------------
Avg Forecast---------------
High Forecast---------------
Low Forecast---------------
Surprise %---------------

Biomea Fusion's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BMEA last annual SG&A of $NaN (undefined).

Biomea Fusion EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts---------------
EPS---------------
Avg Forecast$-0.80$-0.77$-0.71$-0.68$-0.85$-0.82$-0.76$-0.73$-1.21$-1.14$-1.04$-1.00$-0.92$-0.94$-1.08
High Forecast$-0.80$-0.77$-0.71$-0.68$-0.85$-0.82$-0.76$-0.73$-1.21$-1.14$-1.04$-0.90$-0.82$-0.94$-1.08
Low Forecast$-0.80$-0.77$-0.71$-0.68$-0.85$-0.82$-0.76$-0.73$-1.21$-1.14$-1.04$-1.20$-1.08$-0.94$-1.08
Surprise %---------------

According to undefined Wall Street analysts, Biomea Fusion's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BMEA previous annual EPS of $NaN (undefined).

Biomea Fusion Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HOWLWerewolf Therapeutics$2.26$12.00430.97%Buy
BMEABiomea Fusion$8.84$22.75157.35%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
DSGNDesign Therapeutics$5.32$9.6781.77%Buy
EWTXEdgewise Therapeutics$34.48$45.0030.51%Buy
IKNAIkena Oncology$1.72$1.33-22.67%Buy

BMEA Forecast FAQ


Yes, according to 8 Wall Street analysts, Biomea Fusion (BMEA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of BMEA's total ratings.

Biomea Fusion (BMEA) average price target is $22.75 with a range of $11 to $40, implying a 157.35% from its last price of $8.84. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for BMEA stock, the company can go up by 157.35% (from the last price of $8.84 to the average price target of $22.75), up by 352.49% based on the highest stock price target, and up by 24.43% based on the lowest stock price target.

BMEA's average twelve months analyst stock price target of $22.75 supports the claim that Biomea Fusion can reach $13 in the near future.

3 Wall Street analysts forecast a $23.33 price target for Biomea Fusion (BMEA) this month, up 163.91% from its last price of $8.84. Compared to the last 3 and 12 months, the average price target increased by 126.24% and increased by 95.59%, respectively.

Biomea Fusion's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-115M (high $-115M, low $-115M), average SG&A $0 (high $0, low $0), and average EPS is $-3.164 (high $-3.164, low $-3.164). BMEA's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-107M (high $-107M, low $-107M), average SG&A $0 (high $0, low $0), and average EPS is $-2.965 (high $-2.965, low $-2.965).